Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics

Just recently the problem of pharmaceutical residues in the environment has been emphasized by OECD. Especially antibiotics are of concern due to their widespread use and diverse modes of actions including ones that can affect the photosynthetic activity of primary producers and subsequently primary...

Full description

Bibliographic Details
Main Authors: R. Arno Weiss, Thomas Schmidt, Stefan Höger
Format: Article
Language:deu
Published: Swiss Chemical Society 2020-03-01
Series:CHIMIA
Subjects:
Online Access:https://www.ingentaconnect.com/contentone/scs/chimia/2020/00000074/00000003/art00013
id doaj-8c5b8f62ed6c4d91b85e50aa30d3a7ef
record_format Article
spelling doaj-8c5b8f62ed6c4d91b85e50aa30d3a7ef2020-11-25T03:37:19ZdeuSwiss Chemical SocietyCHIMIA0009-42932673-24242020-03-0174318319110.2533/chimia.2020.183Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on AntibioticsR. Arno Weiss0Thomas Schmidt1Stefan Höger2Innovative Environmental Services (IES) Ltd, Benkenstrasse 260, CH-4108 Witterswil, SwitzerlandInnovative Environmental Services (IES) Ltd, Benkenstrasse 260, CH-4108 Witterswil, SwitzerlandInnovative Environmental Services (IES) Ltd, Benkenstrasse 260, CH-4108 Witterswil, SwitzerlandJust recently the problem of pharmaceutical residues in the environment has been emphasized by OECD. Especially antibiotics are of concern due to their widespread use and diverse modes of actions including ones that can affect the photosynthetic activity of primary producers and subsequently primary biomass production and carbon dioxide fixation. The EU regulatory authority, the European Medicines Agency (EMA), has therefore proposed to implement a new tailored environmental risk assessment scheme, published in a new draft guideline 2018. Threshold effect levels to three fixed representative species of green algae and cyanobacteria will be required. This article reviews and compares the contamination of waters with antibiotics in Switzerland and Germany and also presents an overview of published effect data on eukaryotic algae and prokaryotic cyanobacteria in order to discuss the representativeness of the selected species. Since no full datasets as demanded by the EMA were publically available yet, the gaps for four antibiotics have been experimentally completed. In summary the results support the species selection of the EMA published in the revised draft guideline, however it remains unclear whether diatoms should also be considered.https://www.ingentaconnect.com/contentone/scs/chimia/2020/00000074/00000003/art00013antibioticsenvironmental risk assessment (era)eu regulationhuman pharmaceuticalsmeasured environmental concentration (mec)
collection DOAJ
language deu
format Article
sources DOAJ
author R. Arno Weiss
Thomas Schmidt
Stefan Höger
spellingShingle R. Arno Weiss
Thomas Schmidt
Stefan Höger
Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
CHIMIA
antibiotics
environmental risk assessment (era)
eu regulation
human pharmaceuticals
measured environmental concentration (mec)
author_facet R. Arno Weiss
Thomas Schmidt
Stefan Höger
author_sort R. Arno Weiss
title Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
title_short Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
title_full Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
title_fullStr Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
title_full_unstemmed Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics
title_sort challenges of regulatory environmental risk assessment for human pharmaceuticals with focus on antibiotics
publisher Swiss Chemical Society
series CHIMIA
issn 0009-4293
2673-2424
publishDate 2020-03-01
description Just recently the problem of pharmaceutical residues in the environment has been emphasized by OECD. Especially antibiotics are of concern due to their widespread use and diverse modes of actions including ones that can affect the photosynthetic activity of primary producers and subsequently primary biomass production and carbon dioxide fixation. The EU regulatory authority, the European Medicines Agency (EMA), has therefore proposed to implement a new tailored environmental risk assessment scheme, published in a new draft guideline 2018. Threshold effect levels to three fixed representative species of green algae and cyanobacteria will be required. This article reviews and compares the contamination of waters with antibiotics in Switzerland and Germany and also presents an overview of published effect data on eukaryotic algae and prokaryotic cyanobacteria in order to discuss the representativeness of the selected species. Since no full datasets as demanded by the EMA were publically available yet, the gaps for four antibiotics have been experimentally completed. In summary the results support the species selection of the EMA published in the revised draft guideline, however it remains unclear whether diatoms should also be considered.
topic antibiotics
environmental risk assessment (era)
eu regulation
human pharmaceuticals
measured environmental concentration (mec)
url https://www.ingentaconnect.com/contentone/scs/chimia/2020/00000074/00000003/art00013
work_keys_str_mv AT rarnoweiss challengesofregulatoryenvironmentalriskassessmentforhumanpharmaceuticalswithfocusonantibiotics
AT thomasschmidt challengesofregulatoryenvironmentalriskassessmentforhumanpharmaceuticalswithfocusonantibiotics
AT stefanhoger challengesofregulatoryenvironmentalriskassessmentforhumanpharmaceuticalswithfocusonantibiotics
_version_ 1724545791447531520